Table 3.
Multivariate analysis.
| p Value | Exp (B) | 95% CI for Exp (B) Lower upper |
||
|---|---|---|---|---|
| Cancer specific survival | ||||
| ATM | 0.933 | 1.007 | 0.862 | 1.176 |
| ATR | 0.006 | 1.218 | 1.058 | 1.401 |
| DNA-PK | 0.043 | 1.389 | 1.010 | 1.911 |
| XRCC1 | 0.111 | 1.195 | 0.960 | 1.487 |
| Ca125 response | 1.4 × 10− 4 | 1.656 | 1.278 | 2.147 |
| Chemotherapy regimen | 0.659 | 1.115 | 0.687 | 1.811 |
| FIGO stage | 0.025 | 1.420 | 1.046 | 1.928 |
| Grade | 0.002 | 2.029 | 1.300 | 3.166 |
| Residual burden | 0.015 | 1.548 | 1.088 | 2.201 |
| Progression free survival | ||||
| ATM | 0.261 | 0.919 | 0.793 | 1.065 |
| ATR | 0.225 | 1.086 | 0.950 | 1.240 |
| DNA-PK | 0.003 | 1.550 | 1.166 | 2.060 |
| XRCC1 | 0.004 | 1.353 | 1.101 | 1.663 |
| Ca125 response | 1.9 × 10− 9 | 2.230 | 1.716 | 2.898 |
| Chemotherapy regime | 0.200 | 1.323 | 0.863 | 2.028 |
| FIGO stage | 1.6 × 10− 5 | 1.760 | 1.334 | 2.322 |
| Grade | 0.024 | 1.558 | 1.059 | 2.293 |
| Residual burden | 0.002 | 1.612 | 1.194 | 2.177 |
Significant p Values are in bold.